Almirall, S.A. (0O9B.IL)

Compare

9.37

-0.32

(-3.35%)

At close: April 4 at 2:11:37 PM GMT+1

Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology

BARCELONA, Spain, March 21, 2025--Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice.

Business Wire 16 days ago

ALMRY

LBTSF
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin

ORLANDO, Fla., March 07, 2025--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology presents five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting - including new data on tirbanibulin, a topical treatment for actinic keratosis (AK) and progress of its early-stage asset LAD191, a high-affinity monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). These presentations provide valuable insights into pati

Business Wire 30 days ago

ALMRY

LBTSF
Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025

BARCELONA, Spain, March 06, 2025--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced the appointment of Jon U. Garay Alonso as Chief Financial Officer and member of the company’s Management Board as of August 2025, succeeding Mike McClellan, who will leave the company in September 2025, after nearly six successful years as CFO.

Business Wire last month

ALMRY

LBTSF
Three Stocks With Estimated Undervaluation Worth Considering In February 2025

In February 2025, global markets are experiencing a mix of geopolitical tensions and economic uncertainty, with U.S. stocks facing downward pressure due to concerns about consumer spending and potential new tariffs. Amid this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer resilience or growth potential despite broader market challenges.

Simply Wall St. last month

ALMRY

LBTSF

SNCAF
Almirall SA (LBTSF) Q4 2024 Earnings Call Highlights: Surpassing Expectations with Strong ...

Almirall SA (LBTSF) reports a robust 10.2% net sales increase and exceeds EBITDA projections, driven by key products Ilumetri and EBGLYSS.

GuruFocus.com last month

ALMRY
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline

BARCELONA, Spain, February 24, 2025--Almirall, S.A. (ALM):

Business Wire last month

ALMRY

LBTSF
JP Morgan 2025: Almirall updates strategy with focus on medical dermatology

In 2023, medical dermatology represented 52% of Almirall's income with a turnover of EUR465.2m ($477.36m).

Pharmaceutical Technology 2 months ago

ALMRY

GLDAF
Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

SAN FRANCISCO, January 14, 2025--Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, comm

Business Wire 2 months ago

ALMRY

LBTSF
Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

BARCELONA, Spain, December 04, 2024--Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of "The Hive", a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s scientists, creating a unique innovation ecosystem that is aimed at advancing scientific breakthroughs and enhancing research success.

Business Wire 3 months ago

ALMRY

LBTSF
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subject

GlobeNewswire 4 months ago

ELOX

ALMRY

LBTSF
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

BARCELONA, Spain, November 11, 2024--Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. Net Sales increased by 7.9% YoY to a total of €727.6 MM, EBITDA was €142.2 MM (increase of 2.9% YoY) driven by higher sales g

Business Wire 4 months ago

ALMRY

LBTSF
Almirall completes EU regulatory procedure for antifungal Jublia

Onychomycosis is a serious fungal infection impacting an estimated 5.5% of the world's population.

Pharmaceutical Technology 5 months ago

ALMRY
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe

BARCELONA, Spain, October 15, 2024--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis, under the trade name of Jublia®.

Business Wire 5 months ago

ALMRY

LBTSF
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

BARCELONA, Spain, September 25, 2024--More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing. Almirall S.A. (BME: ALM) announced these new long-term results from the ADjoin long-term extension study, which will be presented as a late breaker at the European

Business Wire 6 months ago

ALMRY

LBTSF
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

BARCELONA, Spain, September 23, 2024--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), taking place in Amsterdam from September 25 to 28, 2024. This year, Almirall marks its 80th anniversary, celebrating eight decades of innovation and commitment to delivering products positively impacting people’s health and lives.

Business Wire 6 months ago

ALMRY

LBTSF
Almirall And Two Additional Stocks Considered Below Estimated Market Value

Amidst a complex landscape where global markets display mixed signals, investors are increasingly turning their attention to value and small-cap stocks. This shift comes as major indices like the Dow Jones Industrial Average see notable performance, highlighting a growing divergence from growth stocks which have recently underperformed. In such an environment, identifying undervalued stocks becomes crucial. These are shares that trade below what they are fundamentally worth, offering...

Simply Wall St. 8 months ago

ALMRY

LBTSF

GENI
Ilumetri and Ebglyss spur Almirall’s growth in dermatology

Shares in the company opened 3.9% higher buoyed by an H1 performance in line with expectations.

Pharmaceutical Technology 8 months ago

ALMRY

GLDAF
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales

BARCELONA, Spain, July 22, 2024--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in the second quarter of 2024 which was mainly driven by the dermatology business in Europe. Total Net Sales increased by 6.7% to a total of €497.2 MM, EBITDA was €104.5 MM (increase of 3.2% YoY) driven by higher sales growth, with a gross margin of 65,1%. Dermatology sales

Business Wire 8 months ago

ALMRY

LBTSF
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for addi

GlobeNewswire 8 months ago

ALMRY

LBTSF

ELOX
NICE recommends Ebglyss for atopic dermatitis patients

Almirall’s Ebglyss is predicted to hit blockbuster status in two years in the crowded atopic dermatitis market.

Pharmaceutical Technology 8 months ago

ALMRY

GLDAF

Performance Overview

Return	0O9B.IL	IBEX 35... (^IBEX)
YTD	+15.97%	+7.67%
1-Year	+16.89%	+12.00%
3-Year	-15.27%	+45.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Almirall, S.A. (0O9B.IL)

Almirall's 16th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology

AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin

Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025

Three Stocks With Estimated Undervaluation Worth Considering In February 2025

Almirall SA (LBTSF) Q4 2024 Earnings Call Highlights: Surpassing Expectations with Strong ...

Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline

JP Morgan 2025: Almirall updates strategy with focus on medical dermatology

Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

Almirall completes EU regulatory procedure for antifungal Jublia

Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Almirall And Two Additional Stocks Considered Below Estimated Market Value

Ilumetri and Ebglyss spur Almirall’s growth in dermatology

Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

NICE recommends Ebglyss for atopic dermatitis patients

Performance Overview